I will pay for the following article Management of Patients with Diabetes. The work is to be 17 pages with three to five sources, with in-text citations and a reference page.

I will pay for the following article Management of Patients with Diabetes. The work is to be 17 pages with three to five sources, with in-text citations and a reference page. The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system. Diabetes mellitus (DM) comprises a group of common metabolic disorders that share the phenotype of hyperglycemia. Several distinct types of DM exist and are caused by a complex interaction of genetics, environmental factors, and life-style choices. Depending on the etiology of the DM, factors contributing to hyperglycemia may include reduced insulin secretion, decreased glucose utilization, and increased glucose production. The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system. DM is the leading cause of end-stage renal disease (ESRD), nontraumatic lower extremity amputations, and adult blindness. With an increasing incidence worldwide, DM will be a leading cause of morbidity and mortality for the foreseeable future (Atallah, C. and Amm-Azar, M., 2006).

Categories: The two broad categories of DM are designated type 1 and type 2 on the basis of pathogenic process that leads to hyperglycaemia. Type 1A DM results from autoimmune beta cell destruction, which leads to insulin deficiency. Individuals with type 1B DM lack immunologic markers indicative of an autoimmune destructive process of the beta cells. However, they develop insulin deficiency by unknown mechanisms and are ketosis prone. Type 2 DM is a heterogeneous group of disorders characterized by variable degrees of insulin resistance, impaired insulin secretion, and increased glucose production. Distinct genetic and metabolic defects in insulin action and/or secretion give rise to the common phenotype of hyperglycemia in type 2 DM. Distinct pathogenic processes in type 2 DM have important potential therapeutic implications, as pharmacologic agents that target specific metabolic derangements have become available.&nbsp. &nbsp.